They found that TGF-β2 mRNA levels, with higher expression seen in advanced breast cancer tumors than in early-stage cancer, were inversely related to TGF-β2 protein levels, although TGF-β2 mRNA and protein levels were both related to clinicopathologic prognosticators. The gene discussed is TGFB2; the disease is breast carcinoma.